Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Nivolumab success in untreated metastatic melanoma.

× No keyword cloud information.

6 in total

Review 1. Engineered nanomedicines block the PD-1/PD-L1 axis for potentiated cancer immunotherapy.

Authors: Jun-Hao Li; Lu-Jia Huang; Hui-Ling Zhou; Yi-Ming Shan; Fang-Min Chen; Vesa-Pekka Lehto; Wu-Jun Xu; Li-Qiang Luo; Hai-Jun Yu
Journal: Acta Pharmacol Sin Date: 2022-04-28 Impact factor: 6.150

Review 2. Medication-associated gastrointestinal tract injury.

Authors: Michael Vieth; Elizabeth Montgomery
Journal: Virchows Arch Date: 2017-01-30 Impact factor: 4.535

Review 3. The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy.

Authors: Wenxiao Jiang; Shuya Pan; Xin Chen; Zhi-Wei Wang; Xueqiong Zhu
Journal: Mol Cancer Date: 2021-09-08 Impact factor: 27.401

Review 4. Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway.

Authors: Qian Wu; Li Jiang; Si-Cheng Li; Qiao-Jun He; Bo Yang; Ji Cao
Journal: Acta Pharmacol Sin Date: 2020-03-09 Impact factor: 6.150

5. Development of a radiofrequency ablation platform in a clinically relevant murine model of hepatocellular cancer.

Authors: Xiaoqiang Qi; Guangfu Li; Dai Liu; Anjan Motamarry; Xiangwei Huang; A Marissa Wolfe; Kristi L Helke; Dieter Haemmerich; Kevin F Staveley-O'Carroll; Eric T Kimchi
Journal: Cancer Biol Ther Date: 2015 Impact factor: 4.875

Review 6. Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors.

Authors: Shifaa M Abdin; Dana M Zaher; El-Shaimaa A Arafa; Hany A Omar
Journal: Cancers (Basel) Date: 2018-01-25 Impact factor: 6.639

6 in total